PapersPMID:41758763
Oral Administration of Specific Bioactive Collagen Peptides in the Treatment of Moderate Forms of Atopic Dermatitis: A New Approach.
- findings
- 2
- compound
- 1
- endpoints
- 2
- Study, every finding
- RCT · 3 months
- Dose studied, every finding
- 5 g daily, dissolved in 250 mL water
- Population, every finding
- Adults with moderate atopic dermatitis (SCORAD 15-40), per-protocol population; lesional skin site; corticosteroid cream (triamcinolone) and body lotion permitted in both arms
No finding here moved its endpoint.
What did not
How to read these marks →“Lesional stratum corneum hydration (F(1, 25) = 0.16, p = 0.694, d = 0.155), and lesional TEWL (F(1, 25) = 1.91, p = 0.179, d = 0.553), did not show statistically significant differences between the CP-G and P-G.”
Study record
- Design
- randomised controlled trial
- Species
- human
- Population
- Adults with moderate atopic dermatitis (SCORAD 15-40); bovine type I collagen peptide (CURADERM, GELITA) vs maltodextrin placebo
- Participants
- 30
- Comparator
- placebo
- Duration
- 84 days
- Endpoints measured
- 22